We believe that EVO inhibition of the Ras/MEK/ERK pathway and IAP expression may have led to the higher levels of caspase activity observed in the resistant cancer cells after the combination treatment, thus significantly enhancing the effects of DOX. This evidence concerns the gene MAP2K7 and cancer.